BERKELEY, Calif., Sept. 29, 2006 (PRIMEZONE) -- XOMA Ltd. (Nasdaq:XOMA) today announced its plans for its chief financial officer, Mr. David Boyle, to present an overview of its business strategy and update on the company's pipeline and collaborations, as well as his availability for meetings with investors, at the following conferences:
The Sachs Associates Biotech in Europe Investor Forum at the Swissotel in Zurich, Switzerland, on Wednesday October 4, 2006 at 12:05 p.m. local time. Interested parties can make 1-on-1 meeting requests directly through the conference website at http://www.sachsforum.com/zurich06.html. XOMA will post a copy of Mr. Boyle's presentation on the investor page at http://investors.xoma.com/index.cfm.
The Biotechnology Industry Organization's Investor Forum at the Palace Hotel in San Francisco, California on Wednesday October 18, 2006 at 12:00 p.m. Pacific time. For information on scheduling a 1-on-1 meeting with XOMA, please contact Amy Deiner at adeiner@bio.org. A webcast of the presentation will be available at www.bio.org and http://investors.xoma.com/index.cfm.
Rodman & Renshaw's 8th Annual Healthcare Conference at the New York Palace Hotel in New York City on Tuesday November 7, 2006 at 3:55 p.m. Eastern time. Parties interested in scheduling 1-on-1 meetings are invited to contact Lily Khaykina at LK@rodmanandrenshaw.com. An audio webcast of the presentation will be available live at http://wsw.com/webcast/rrshq8/xoma. An archived version of the webcast will be available at this web address for 90 days following the presentation.
About XOMA
XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono, SA) to treat moderate-to-severe plaque psoriasis, and LUCENTIS(tm) (ranibizumab injection), a monoclonal antibody product marketed worldwide (by Genentech and Novartis AG) to treat neovascular (wet) age-related macular degeneration.
The company has built a premier antibody discovery and development platform that includes access to seven of the leading commercially available antibody phage display libraries and XOMA's proprietary Human Engineering(tm) and bacterial cell expression (BCE) technologies. More than 45 companies have signed BCE licenses. XOMA's development collaborators include Lexicon Genetics, Inc., Novartis, and Schering-Plough Corp. With a fully integrated product development infrastructure, XOMA's product development capabilities extend from preclinical sciences to product launch. For more information, please visit the company's website at www.xoma.com.
Certain statements contained herein concerning current collaborations and product development, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including those related to the results of pre-clinical testing, the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data), changes in the status of the existing collaborative relationships, the ability of collaborators and other partners to meet their obligations, market demand for products, scale up and marketing capabilities, competition, uncertainties regarding the status of biotechnology patents, uncertainties as to the cost of protecting intellectual property and risks associated with XOMA's status as a Bermuda company, are described in more detail in the Company's most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in considering XOMA's prospects.